• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Human epidermal growth factor receptor 2 testing recommendation.

作者信息

Raji Adekunle

出版信息

J Clin Oncol. 2007 Sep 1;25(25):4020-1; author reply 4021-3. doi: 10.1200/JCO.2007.11.7580.

DOI:10.1200/JCO.2007.11.7580
PMID:17761990
Abstract
摘要

相似文献

1
Human epidermal growth factor receptor 2 testing recommendation.人表皮生长因子受体2检测建议
J Clin Oncol. 2007 Sep 1;25(25):4020-1; author reply 4021-3. doi: 10.1200/JCO.2007.11.7580.
2
Human epidermal growth factor receptor 2 testing in breast cancer.乳腺癌中的人表皮生长因子受体2检测
J Clin Oncol. 2007 Sep 1;25(25):4020; author reply 4021-3. doi: 10.1200/JCO.2007.10.8522.
3
Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
J Clin Oncol. 2008 Mar 20;26(9):1571. doi: 10.1200/JCO.2008.16.6868.
4
Current status of HER2 testing: caught between a rock and a hard place.
Am J Clin Pathol. 2001 Dec;116(6):806-10. doi: 10.1309/WMN8-VTR5-DUGF-X12L.
5
Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
Cancer. 2010 Aug 15;116(16):3980-1; author reply 3981. doi: 10.1002/cncr.25186.
6
Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Am J Clin Pathol. 2006 Jan;125(1):155-6.
7
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.美国临床肿瘤学会/美国病理学家学会指南中人类表皮生长因子受体2评分从10%变更为30%的定量依据：乳腺癌中的肿瘤异质性及其对基于组织微阵列的预后评估的影响
J Clin Oncol. 2007 Dec 1;25(34):5418-25. doi: 10.1200/JCO.2007.12.8033.
8
Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.在评估浸润性乳腺癌的雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER-2）时，手术标本可用芯针活检样本替代。
Acta Oncol. 2008;47(1):38-46. doi: 10.1080/02841860701441822.
9
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
J Clin Oncol. 2008 Apr 1;26(10):1768-9; author reply 1769-71. doi: 10.1200/JCO.2007.15.6141.
10
Luminal B breast tumors are not HER2 positive.管腔B型乳腺肿瘤不是HER2阳性。
Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26.

引用本文的文献

1
Application of ultrasound-based radiomics models of breast masses to predict invasive components of encapsulated papillary carcinoma.基于超声的乳腺肿块放射组学模型在预测包膜内乳头状癌浸润成分中的应用。
Quant Imaging Med Surg. 2023 Oct 1;13(10):6887-6898. doi: 10.21037/qims-22-1069. Epub 2023 Sep 15.
2
Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer.术前超声特征联合临床因素预测 HER2 阳性型（非腔面）乳腺癌。
BMC Med Imaging. 2021 Dec 2;21(1):184. doi: 10.1186/s12880-021-00714-0.